Avalanche Biotechnologies Inc (ADVM)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Amber Salzman
Employees:
82
1035 O'BRIEN DRIVE, MENLO PARK, CA 94025
650-272-6269

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Data derived from most recent annual or quarterly report
Market Cap 156.062 Million Shares Outstanding98.152 Million Avg 30-day Volume 1.561 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.39
Price to Revenue0.0 Debt to Equity0.0 EBITDA-111.714 Million
Price to Book Value2.4407 Operating Margin0.0 Enterprise Value630.381 Million
Current Ratio20.815 EPS Growth-0.366 Quick Ratio20.59
1 Yr BETA 0.8507 52-week High/Low 14.6 / 1.47 Profit Margin0.0
Operating Cash Flow Growth-61.2589 Altman Z-Score11.9655 Free Cash Flow to Firm -78.261 Million
View SEC Filings from ADVM instead.

View recent insider trading info

Funds Holding ADVM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADVM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

50 Thousand total shares from 3 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SEYEDKAZEMI SETAREH CHIEF DEVELOPMENT OFFICER

  • Officer
600 2022-01-06 2

FISCHER LAURENT CEO, PRESIDENT AND DIRECTOR

  • Officer
  • Director
737,462 2021-12-08 4

SOPARKAR PETER SEE REMARKS SECTION

  • Officer
258,631 2021-12-08 3

D'SOUZA RUPERT CHIEF FINANCIAL OFFICER

  • Officer
400,000 2021-12-06 2

SCOPA JAMES PAUL

  • Director
3,334 2021-11-15 2

CLARK JULIE CHIEF MEDICAL OFFICER

  • Officer
164,723 2021-09-30 4

THRIFT JACK ANTHONY INTERIM CFO

  • Officer
0 2021-09-02 1

RILEY BRIGIT CHIEF SCIENTIFIC OFFICER

  • Officer
120,000 2021-09-02 1

THEDINGA ANGELA CHIEF TECHNOLOGY OFFICER

  • Officer
270,000 2021-08-06 2

DERESPINO CHRISTOPHER SEE REMARKS

  • Officer
0 2021-06-24 1

WHITCUP SCOTT M

  • Director
40,000 2021-05-12 1

MACHADO PATRICK

  • Director
52,500 2021-05-12 2

SVORONOS DAWN

  • Director
40,000 2021-05-12 2

GASMI MEHDI

  • Director
40,000 2021-05-12 1

WOIWODE THOMAS

  • Director
40,000 2021-05-12 1

LUPHER, JR. MARK L.

  • Director
40,000 2021-05-12 1

TUCKSON REED VAUGHN

  • Director
45,000 2021-02-19 2

PATTERSON LEONE D PRESIDENT AND CFO

  • Officer
0 2021-02-16 2

OSBORNE AARON CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-16 1

CARTER ERIC G

  • Director
0 2020-06-23 0

HEMRAJANI REKHA

  • Director
0 2020-06-23 0

LEUNG THOMAS CHIEF FINANCIAL OFFICER

  • Officer
0 2020-02-20 0

FINER MITCHELL H.

  • Director
0 2019-07-31 0

SPIVEY RICHARD N.

  • Director
0 2019-07-31 0

CHENG JENNIFER C. GENERAL COUNSEL

  • Officer
0 2019-02-14 0

CLEVELAND PAUL B

  • Director
0 2018-05-31 0

COUNTOURIOTIS ATHENA SVP, CHIEF MEDICAL OFFICER

  • Officer
0 2018-02-15 0

SALZMAN AMBER PRESIDENT AND CEO

  • Officer
  • Director
0 2018-02-15 0

SCHWARTZ STEVEN DANIEL

  • Director
398,991 2017-06-12 0

BARONE SAMUEL B. SVP, CLINICAL DEVELOPMENT

  • Officer
172,335 2017-02-09 0

VERSANT VENTURES IV, LLC

VERSANT VENTURE CAPITAL IV, L.P.

VERSANT IV LUXCO S.A R.L.

VERSANT CAPITAL IV (SWITZERLAND) GMBH

  • 10% Owner
7,003,892 2016-05-11 0

RUSSO CARLO EVP AND CHIEF MEDICAL OFFICER

  • Officer
0 2016-05-11 0

WACHTER PAUL

  • Director
69,112 2016-02-29 0

MCLAUGHLIN JOHN PETER

  • Director
36,893 2016-02-12 0

BLUMENKRANZ MARK S.

  • Director
562,915 2016-02-12 0

RUBIO ROMAN G. SVP, TRANSLATIONAL MEDICINE

  • Officer
165,650 2016-02-12 0

BRAUN SHIRLEY VP, HUMAN RESOURCES

  • Officer
161,140 2016-02-12 0

SWARTZBURG MICHAEL PRINCIPAL ACCOUNTING OFFICER

  • Officer
82,113 2016-02-12 0

BAIN LINDA CHIEF FINANCIAL OFFICER

  • Officer
41,930 2015-08-21 0

HULL HANS CHIEF EXECUTIVE OFFICER

  • Officer
137,210 2015-08-21 0

CHALBERG THOMAS W. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
1,099,401 2015-06-10 0

GUERIN JOHN PATRICK ET AL

  • Director
  • 10% Owner
200,000 2015-05-27 0

ZYGTECH, LLC

  • 10% Owner
No longer subject to file 2015-04-13 0

REGENERON PHARMACEUTICALS INC

  • 10% Owner
No longer subject to file 2014-08-05 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

DEERFIELD MGMT III, L.P.

DEERFIELD MANAGEMENT CO

DEERFIELD PRIVATE DESIGN FUND III, L.P.

DEERFIELD PARTNERS, LP

DEERFIELD INTERNATIONAL MASTER FUND, L.P.

  • 10% Owner
  • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
No longer subject to file 2014-08-05 0

VENROCK ASSOCIATES VI, L.P.

VENROCK PARTNERS VI, L.P.

VENROCK MANAGEMENT VI, LLC

VENROCK PARTNERS MANAGEMENT VI, LLC

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP CO-INVESTMENT HOLDINGS, LLC

VHCP MANAGEMENT, LLC

HOVE ANDERS D

KOH BONG Y

  • 10% Owner
4,330,942 2014-08-05 0

VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

VHCP CO-INVESTMENT HOLDINGS II, LLC

VHCP MANAGEMENT II, LLC

  • 10% Owner
4,330,942 2014-08-05 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD MGMT III, L.P.

DEERFIELD PRIVATE DESIGN FUND III, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
0 2014-07-30 0

VENROCK ASSOCIATES VI, L.P.

VENROCK PARTNERS VI, L.P.

VENROCK MANAGEMENT VI, LLC

VENROCK PARTNERS MANAGEMENT VI, LLC

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP CO-INVESTMENT HOLDINGS, LLC

VHCP MANAGEMENT, LLC

ROBERTS BRYAN E

HOVE ANDERS D

  • 10% Owner
0 2014-07-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SEYEDKAZEMI SETAREH - Officer CHIEF DEVELOPMENT OFFICER

2022-01-10 17:04:47 -0500 2022-01-06 A 425,000 a 425,000 direct

FISCHER LAURENT - Director - Officer CEO, PRESIDENT AND DIRECTOR

2021-12-10 17:26:36 -0500 2021-12-09 P 14,323 $1.85 a 737,462 direct -4.8387 0.0 0.0 1 -4.8387 2

SOPARKAR PETER - Officer SEE REMARKS SECTION

2021-12-10 17:26:01 -0500 2021-12-08 P 25,000 $1.91 a 258,631 direct -4.8387 0.0 0.0 1 -4.8387 2

FISCHER LAURENT - Director - Officer CEO, PRESIDENT AND DIRECTOR

2021-12-10 17:26:36 -0500 2021-12-08 P 10,677 $1.79 a 723,139 direct -4.8387 0.0 0.0 1 -4.8387 2

D'SOUZA RUPERT - Officer CHIEF FINANCIAL OFFICER

2021-12-08 17:26:21 -0500 2021-12-06 A 400,000 a 400,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 19:15:03 UTC -0.1925 0.2625 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 18:45:03 UTC -0.1925 0.2625 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 18:15:03 UTC -0.1925 0.2625 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 17:45:03 UTC -0.1925 0.2625 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 17:15:03 UTC -0.1925 0.2625 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 16:45:04 UTC -0.1905 0.2605 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 16:15:03 UTC -0.1905 0.2605 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 15:45:03 UTC -0.1905 0.2605 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 15:15:03 UTC -0.1905 0.2605 2500000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 14:45:04 UTC -0.1905 0.2605 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 14:15:03 UTC -0.1905 0.2605 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 13:45:03 UTC -0.3447 0.4147 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 13:15:03 UTC -0.3447 0.4147 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-25 12:45:03 UTC -0.3447 0.4147 2400000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-24 22:15:03 UTC -0.3391 0.4091 2200000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-24 21:45:03 UTC -0.3391 0.4091 2200000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-24 21:15:03 UTC -0.3391 0.4091 2200000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-24 20:45:03 UTC -0.3391 0.4091 2200000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-24 20:15:04 UTC -0.3391 0.4091 2200000
ADVERUM BIOTECHNOLOGIES INC ADVM 2022-01-24 19:45:04 UTC -0.329 0.399 2200000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Trust for Professional Managers- Convergence Market Neutral Fund ADVM -5066.0 shares, $-61805.2 2020-08-31 N-PORT

Elevate your investments